Famotidine · FAMOTIDINE 10 mg/mL · Injection, Solution · Intravenous · Fresenius Kabi USA, LLC
NDC 63323-0739-16 · 25 VIAL, SINGLE-USE in 1 TRAY / 2 mL in 1 VIAL, SINGLE-USE · ANDA · View full market →
5 companies supply this market — a reasonable cushion if one runs into trouble. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.6% of the time — roughly 4× the typical drug (0.1%).
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is 4× that.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Fresenius Kabi USA, LLC | FAMOTIDINE 10 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Sagent Pharmaceuticals | FAMOTIDINE 4 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Sagent Pharmaceuticals | FAMOTIDINE 10 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Baxter Healthcare Corporation | FAMOTIDINE 20 mg/50mL | Jul 15, 2026 | Sep 2, 2026 |
| HF Acquisition Co LLC, DBA HealthFirst | FAMOTIDINE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Medical Purchasing Solutions, LLC | FAMOTIDINE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Athenex Pharmaceutical Division, LLC. | FAMOTIDINE 10 mg/mL | Jul 15, 2026 | Jul 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Famotidine — NDC 63323-0739-16," retrieved September 3, 2026, https://drugdashboards.com/drug/63323073916.
Free to cite with attribution — see how the data is put together.